Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs
|Chronic Renal Failure||Biological: Pancreatic enzimes Device: Creon ®||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
|Official Title:||STUDY OF EFFECTIVENESS OF THE USE OF PANCREATIC ENZYME: NORZYME® -(MADE IN THE LABORATORY PANCREALIPASE BERGAMO) INPATIENTS WITH PANCREATIC INSUFFICIENCY IN USE SUBSTITUTEENZYMATIC WHEN COMPARED TO PRODUCT CREON®|
- Balance of fat in feces. [ Time Frame: 06 weeks of treatment. ]
- Prove the efficacy of pancreatic enzyme Norzyme ® through the activity of lipase in the formulation contained in the control of steatorrhea [ Time Frame: 06 weeks of treatment. ]
|Study Start Date:||June 2007|
|Estimated Study Completion Date:||December 2011|
|Estimated Primary Completion Date:||November 2011 (Final data collection date for primary outcome measure)|
Biological: Pancreatic enzimes
- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
|Active Comparator: Creon®||
Device: Creon ®
- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
Phase III clinical trial systematic sampling, double-blind, randomized, crossed that evaluates the comparative efficacy of a formulation containing enzyme pancreas in 16 patients with pancreatic insufficiency exogenous of any cause. The study will be conducted with the inclusion of 16 adult patients, both sexes, regardless of color or social class, aged 14 to 65 years, clinically diagnosed as having pancreatic insufficiency exocrine any etiology (cystic fibrosis, cancer, pancreatectomy, Surgery by trauma). The Research Subjects will be recruited with the help of medical coinvestigador specialist Dr. Francisco Callejas Neto, who will offer their clinic patients to participate in the study. If there is interest from same, all are invited to attend the Clinic for total LAL clarification about the study of drug action, benefits, possible risks, compensation, study period, and finally understanding reading and signing together with the investigator of the Term of Consent.
The research subjects will have complete freedom to lead to the Informed Consent house, where they can review all items easy. After informed and the consent form and signed informed, patients will be examined by the researcher LAL Clinic which will perform a physical examination in the same general and specific. Will rated their personal background and reviewed the Inclusion and Excluded from the study.
Satisfying the criteria for inclusion in the study subjects are approved to participate in the study.
The 16 Subjects Research approved within the inclusion criteria and exclusion to participate in the study be included in the study as sequential by the number of their care. Later, the same will be inserted in randomization table, which was outlined in a randomized crossover for two drugs, the randomization scheme will be in the balanced cross 2 x 2. A design is said to be balanced if it satisfies the following conditions:
· Each medication is applied only once in each subject;
• in each period, the number of subjects receiving each medicine must be equal; This randomization was previously performed by the computer program and by a qualified professional Prof. Dr. Yuko Wada Cilicia (PhD in Biostatistics and PhD of Biostatistics, UNICAMP) of Statpharm Scientific Consulting Ltda.
All study medication will be labeled according to the randomization, previously performed by pharmacy LAL Clinica, which should make conference material for 3 checks. In each period of the study medication should be labeled with the following words: code of the subject during the study period and dose to be administered in the same. All these procedures should be made to minimize and avoid bias in the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01228643
|LAL Clinica Pesquisa e Desenvolvimento LTDA|
|Valinhos, SP, Brazil, 13271000|
|Principal Investigator:||Alexandre Frederico, Doctor||LAL Clinical Reseach e Development Ltda|